ELASTY® G Plus with Lidocaine – HA Dermal Filler | 1 × 1ml

Product Overview

ELASTY® G Plus with Lidocaine is a professional cross-linked Hyaluronic Acid (HA) dermal filler developed for medium to deep wrinkle correction, facial volume restoration, structural tissue support and advanced facial contouring.

Manufactured in South Korea, ELASTY® G Plus contains 24mg/ml Hyaluronic Acid and 0.3% Lidocaine, combining a firmer, higher-viscosity HA gel with a local anaesthetic designed to improve patient comfort during treatment.

Manufactured using PNET® – Preserved Natural Entanglement Technology, ELASTY® G Plus features a cohesive, elastic Hyaluronic Acid gel matrix developed to provide volume, projection and structural support within appropriately selected facial areas.

Positioned among the firmer formulations in the ELASTY® range, G Plus is intended for aesthetic treatments where greater structural correction is required than would typically be achieved with softer dermal fillers.

Potential professional treatment objectives include:

• Medium to deep wrinkle correction

• Facial volume restoration

• Structural tissue support

• Cheek and mid-face enhancement

• Chin augmentation

• Facial contour refinement

• Correction of selected deep facial folds

• Restoration of age-related facial volume loss

• Facial projection and profile balancing

The cross-linked HA formulation provides immediate physical correction following appropriate placement, while its cohesive gel characteristics are designed to support the intended facial contours.

ELASTY® G Plus also contains 0.3% Lidocaine, incorporated to help reduce injection-related discomfort.

Unlike non-cross-linked skin boosters or regenerative Polynucleotide products, ELASTY® G Plus is designed primarily for physical volume restoration, wrinkle correction and structural facial enhancement.

ELASTY® G Plus is intended strictly for appropriately qualified medical or aesthetic professionals trained in advanced dermal filler procedures.

Pack Contents

Each pack contains:

• 1 × 1ml pre-filled syringe of ELASTY® G Plus

• Hyaluronic Acid: 24mg/ml

• Lidocaine: 0.3%

• 2 × 27G ½" sterile needles, as specified in the supplied product information

• Sterile, sealed professional-use packaging

Volume per Syringe: 1ml

Total Product Volume: 1ml

Always verify the contents against the physical packaging, manufacturer labelling and current Instructions for Use before administration.

Product Composition

Cross-Linked Hyaluronic Acid – 24mg/ml

ELASTY® G Plus contains 24mg/ml Hyaluronic Acid within a cohesive, cross-linked injectable dermal filler gel.

Hyaluronic Acid is naturally present within human tissues and contributes to hydration and extracellular matrix function.

Cross-linking improves the mechanical stability and persistence of the HA gel compared with non-cross-linked formulations, allowing it to provide physical correction and tissue support.

Within ELASTY® G Plus, the HA gel is designed to support:

• Facial volume restoration

• Structural tissue support

• Medium to deep wrinkle correction

• Facial contour enhancement

• Projection

• Shape retention

• Natural-looking augmentation

Its firmer gel characteristics make it particularly relevant to treatments requiring greater support than a softer HA filler.

Lidocaine – 0.3%

ELASTY® G Plus contains 0.3% Lidocaine.

Lidocaine is a local anaesthetic incorporated into the formulation to help reduce injection-related discomfort and improve patient comfort.

Patients should be assessed for relevant allergies, hypersensitivities and contraindications before treatment.

Highly Purified Hyaluronic Acid

The ELASTY® range uses purified Hyaluronic Acid within professional injectable gel formulations developed for aesthetic correction and soft tissue augmentation.

Cohesive HA Gel Matrix

The gel is designed to provide a combination of:

• High elasticity

• Strong cohesion

• Structural stability

• Volume retention

• Tissue support

• Controlled product delivery

• Facial contour definition

These properties are intended to support durable correction following appropriate professional placement.

PNET® – Preserved Natural Entanglement Technology

ELASTY® dermal fillers are developed using PNET® – Preserved Natural Entanglement Technology, the brand's proprietary Hyaluronic Acid gel technology.

PNET® is designed to preserve the natural entanglement characteristics of HA chains while producing a cohesive and structurally stable gel matrix.

Preserved HA Chain Entanglement

The technology is designed around preserving the natural entanglement of Hyaluronic Acid chains within the gel structure.

High Elasticity

Elasticity supports the gel's ability to provide correction while responding appropriately to movement and mechanical forces within the treated tissue.

Strong Cohesion

Cohesion helps maintain gel integrity and supports the intended contour following appropriate placement.

Structural Gel Support

The firmer gel matrix is designed to provide greater physical support in areas requiring volume restoration, projection or contour enhancement.

Controlled Product Delivery

The formulation is designed to support smooth and controlled extrusion during professional administration.

Volume Retention

The cross-linked HA matrix is designed to maintain its intended volumising and contouring effect over time.

Together, these characteristics position ELASTY® G Plus as a structurally supportive filler for deeper correction and facial contouring.

High-Viscosity HA Formulation

ELASTY® G Plus is positioned as a firmer, higher-viscosity formulation within the core ELASTY® range.

Its gel characteristics are intended to provide greater support and projection than softer fillers primarily designed for delicate or superficial correction.

Potential treatment objectives include:

• Deep wrinkle correction

• Restoration of facial volume

• Improved contour definition

• Structural tissue support

• Correction of selected facial folds

• Profile enhancement

The appropriate product should always be selected according to its rheological characteristics, manufacturer-authorised indications and individual patient anatomy.

Facial Volume Restoration

Age-related changes may result in redistribution or loss of facial volume, contributing to altered facial contours and proportions.

ELASTY® G Plus is designed to provide physical volume restoration within appropriately selected treatment areas.

Potential objectives may include:

• Restoring selected areas of facial volume

• Improving facial contours

• Supporting cheek and mid-face structure

• Correcting appropriate volume deficiencies

• Improving facial balance

• Providing natural-looking augmentation

Treatment should focus on proportionate restoration rather than unnecessary overcorrection.

Structural Support & Facial Projection

The firmer gel characteristics of ELASTY® G Plus are designed to support treatments requiring greater structural correction.

Potential professional objectives include:

• Improved facial projection

• Structural contour enhancement

• Chin definition

• Cheek contour refinement

• Lower-face support

• Facial profile balancing

Treatment planning should consider facial anatomy, tissue characteristics, existing proportions and the patient's desired aesthetic outcome.

Medium to Deep Wrinkle Correction

ELASTY® G Plus is developed for the correction of medium to deep facial wrinkles and folds.

The supplied product information particularly references the correction of nasolabial folds.

Potential treatment objectives include:

• Softening selected deeper facial folds

• Restoring support to areas of volume loss

• Improving facial transitions

• Reducing the appearance of appropriate wrinkles

• Supporting natural-looking facial rejuvenation

Treatment suitability should always be determined according to wrinkle depth, tissue condition and the manufacturer's authorised indications.

Product-Specific Clinical Information

The supplied product information references ELASTY® G Plus clinical trial results involving 63 subjects.

According to that information, the product demonstrated:

• Temporary improvement in nasolabial folds

• Volume creation within the forehead region

• Volume creation within the temple region

These findings are presented as manufacturer-referenced clinical information rather than independently verified comparative evidence.

The supplied summary does not establish the study design, follow-up duration, magnitude of improvement or adverse-event rates.

Practitioners should consult the complete manufacturer documentation and current Instructions for Use when evaluating clinical evidence and authorised treatment indications.

Key Benefits

• Professional cross-linked HA dermal filler

• 1 × 1ml pre-filled syringe

• 24mg/ml Hyaluronic Acid

• 0.3% Lidocaine

• 2 × 27G ½" needles, as specified

• Manufactured using PNET® technology

• Firmer, higher-viscosity HA gel

• Strong cohesion

• High elasticity

• Designed for structural tissue support

• Supports facial volume restoration

• Supports medium to deep wrinkle correction

• Helps improve selected nasolabial folds

• Supports facial contour definition

• Designed to provide projection

• Supports selected cheek and mid-face treatments

• Suitable for selected chin augmentation protocols

• Supports correction of age-related volume loss

• Provides immediate physical correction

• Designed for controlled product delivery

• Lidocaine-containing formulation supports treatment comfort

• Product-specific clinical information referenced by the manufacturer

• Intended strictly for appropriately qualified professional use

Common Treatment Areas

The supplied product information identifies potential treatment areas including:

• Nasolabial folds

• Forehead volume restoration

• Temple volume restoration

• Cheeks and mid-face

• Chin

• Facial contour refinement

• Selected nasal contouring procedures

• Areas of moderate to significant facial volume loss

• Deep facial folds

• Lower-face structural support

• Facial profile balancing

• Selected advanced facial augmentation procedures

Important anatomical considerations

The forehead, temples and nose are anatomically high-risk regions for injectable dermal filler treatment.

Potential complications in these regions include vascular occlusion, tissue necrosis and visual impairment, including blindness.

A treatment area being mentioned in manufacturer-related promotional material or clinical research does not automatically establish that it is an authorised indication for every market or product presentation.

Treatment suitability must always be determined according to:

• Current manufacturer-authorised indications

• Facial and vascular anatomy

• Tissue characteristics

• Degree of volume loss

• Required level of projection

• Previous aesthetic procedures

• Practitioner competence

• Individual treatment objectives

Always follow the manufacturer's current Instructions for Use regarding treatment areas, administration technique, treatment depth, product volume and placement.

ELASTY® F Plus vs ELASTY® G Plus

ELASTY® F Plus and G Plus are distinct formulations designed for different levels of aesthetic correction.

ELASTY® F Plus

Positioned primarily for:

• Fine to moderate wrinkles

• Softer tissue correction

• Subtle volume restoration

• Selected facial folds

• Natural-looking rejuvenation

• Balanced flexibility and support

Primary focus: Refined correction and moderate soft tissue augmentation.

ELASTY® G Plus

Positioned primarily for:

• Medium to deep wrinkles

• Greater facial volume restoration

• Structural tissue support

• Facial projection

• Deep contour enhancement

• Selected advanced augmentation treatments

Primary focus: Deeper correction, volume restoration and structural facial contouring.

Both supplied formulations contain:

• 24mg/ml Hyaluronic Acid

• 0.3% Lidocaine

However, they should not be considered interchangeable solely because their HA and Lidocaine concentrations are the same.

Their intended gel characteristics, product specifications and authorised indications should guide professional product selection.

ELASTY® G Plus vs Standard ELASTY® G

Standard ELASTY® G and ELASTY® G Plus should be treated as separate product variants.

Based on the supplied information:

Standard ELASTY® G

• Cross-linked HA dermal filler

• 24mg/ml Hyaluronic Acid

• High-density formulation

• Positioned for deep volume and structural contouring

• Supplied as 2 × 1ml in the previous product information

ELASTY® G Plus

• Cross-linked HA dermal filler

• 24mg/ml Hyaluronic Acid

• 0.3% Lidocaine

• Firmer structural formulation

• Supplied as 1 × 1ml

• Two 27G ½" needles, according to the supplied specification

The Lidocaine-containing formulation is intended to improve patient comfort during professional administration.

Specifications should not be transferred between standard and Plus variants without confirmation from the exact product packaging.

ELASTY® G Plus vs Skin Boosters

ELASTY® G Plus should not be confused with a non-cross-linked Hyaluronic Acid skin booster.

HA Skin Boosters

These products primarily focus on:

• Hydration

• Moisture retention

• Skin texture

• Elasticity

• General skin-quality improvement

ELASTY® G Plus

As a cross-linked dermal filler, G Plus is designed primarily for:

• Physical volume restoration

• Structural support

• Projection

• Wrinkle correction

• Facial contour enhancement

Its principal purpose is structural aesthetic correction rather than general skin hydration or regenerative biostimulation.

Recommended Treatment Approach

ELASTY® G Plus should only be administered following comprehensive professional assessment.

The supplied product information describes the following general approach:

• Initial Treatment: Single treatment session

• Product Volume: Individually determined

• Treatment Technique: Selected according to anatomy, practitioner training and manufacturer guidance

• Treatment Depth: Determined according to treatment area and current Instructions for Use

• Review: Commonly approximately 2–4 weeks following treatment

• Additional Correction: Considered following clinical reassessment where appropriate

• Maintenance: Individually determined according to product persistence and treatment goals

This should not be interpreted as a universal treatment protocol.

The manufacturer's current Instructions for Use should always take precedence.

Professional Treatment Considerations

ELASTY® G Plus should only be administered by appropriately qualified and trained medical or aesthetic professionals with suitable competence in advanced dermal filler procedures.

Treatment planning should include:

• Comprehensive patient consultation

• Full medical history

• Detailed facial assessment

• Assessment of facial proportions

• Assessment of structural volume loss

• Evaluation of tissue characteristics

• Evaluation of vascular anatomy

• Review of previous dermal filler treatments

• Assessment of contraindications

• Consideration of Lidocaine-related contraindications

• Discussion of realistic treatment expectations

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Practitioners should have appropriate training in facial vascular anatomy, complication prevention, recognition of vascular compromise and emergency management.

Treatment depth, technique, product volume and distribution should always be determined according to individual anatomy and the manufacturer's current Instructions for Use.

Results & Treatment Outcomes

ELASTY® G Plus provides immediate physical volume and contour correction following appropriate professional placement.

Potential outcomes may include:

• Improved facial volume

• Smoother-looking deep facial folds

• Enhanced cheek contours

• Improved chin projection

• Improved facial proportions

• Greater contour definition

• Improved facial balance

• Natural-looking structural rejuvenation

Initial treatment-related swelling may temporarily influence the appearance of the treated area.

The final aesthetic outcome becomes clearer as swelling subsides and the filler integrates within the surrounding tissues.

Results & Longevity

The supplied professional product information describes results as commonly lasting approximately:

8–12 months

This should be considered an approximate range rather than a guaranteed duration.

Individual longevity may vary according to:

• Treatment area

• Product volume

• Treatment technique

• Treatment depth

• Patient metabolism

• Facial movement

• Patient age

• Lifestyle

• Tissue characteristics

• Individual biological response

Maintenance treatment may subsequently be considered following professional reassessment.

Storage & Handling

ELASTY® G Plus should be stored and handled according to the manufacturer's current Instructions for Use and the information supplied with the original product.

To maintain product integrity:

• Keep the product within its original packaging until required.

• Follow manufacturer-specified storage conditions.

• Protect from inappropriate environmental exposure.

• Inspect the syringe and outer packaging before use.

• Check the batch number and expiry date.

• Verify product authenticity and traceability.

• Maintain appropriate aseptic handling procedures.

• Do not use if sterile packaging is damaged.

• Do not use if the syringe appears compromised.

• Do not use after the stated expiry date.

Each syringe is intended for single use according to the manufacturer's Instructions for Use.

Important Information

ELASTY® G Plus with Lidocaine is intended strictly for use by appropriately qualified and trained medical or aesthetic professionals.

Professional knowledge of the following is essential:

• Facial anatomy

• Vascular anatomy

• Advanced dermal filler techniques

• Appropriate treatment planes

• Patient selection

• Aseptic practice

• Lidocaine-containing injectable products

• Complication prevention

• Recognition of vascular compromise

• Emergency management

• Dermal filler complication management

Patient Assessment

Treatment should only proceed following:

• Full patient consultation

• Comprehensive medical history

• Detailed facial assessment

• Examination of the proposed treatment area

• Review of previous aesthetic treatments

• Assessment of contraindications

• Assessment of known allergies and hypersensitivities

• Consideration of Lidocaine-related contraindications

• Discussion of expected outcomes

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Contraindications & Precautions

The supplied product information does not provide a complete manufacturer-defined contraindication list.

Treatment suitability should be carefully assessed where relevant factors include:

• Active infection or inflammation within the treatment area

• Known hypersensitivity to product components

• Known Lidocaine hypersensitivity

• Pregnancy or breastfeeding

• Uncontrolled medical conditions

• Other contraindications identified within the manufacturer's current Instructions for Use

This list is not exhaustive.

Potential Treatment Reactions

Temporary effects associated with injectable dermal filler treatment may include:

• Redness

• Swelling

• Bruising

• Tenderness

• Discomfort

• Localised firmness

• Temporary contour irregularity

The exact product-specific adverse-event profile should be confirmed from the manufacturer's current Instructions for Use.

Serious Dermal Filler Complications

Injectable dermal filler procedures can result in serious complications, including infection, inflammatory reactions and vascular complications.

Inadvertent intravascular administration may result in vascular occlusion and tissue injury.

Depending upon the anatomical area involved, complications can include tissue necrosis, visual impairment or blindness.

Practitioners must be appropriately trained in recognising and managing vascular compromise and other filler-related complications.

Patients should receive appropriate written aftercare information and clear guidance regarding symptoms requiring urgent medical assessment.

Always consult the manufacturer's current Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, administration and potential adverse events.

For appropriately qualified professional use only.